Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs

Regulatory Peptides

Volumn 162, Issue 1-3, 2010, Pages 73-78

  Liu, Enzhao ^a   Yang, Shengrong ^a   Xu, Zhao ^a   Li, Jian ^a   Yang, Wansong ^a   Li, Guangping ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin (1 7); Atrial fibrillation; Fibrosis; Remodeling

Indexed keywords

ANGIOTENSIN[1-7]; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG MECHANISM; FEMALE; FIBROSIS; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FIBROSIS; HEART ATRIUM PACING; HISTOPATHOLOGY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA;

ANGIOTENSIN I; ANIMALS; ATRIAL FIBRILLATION; BASE SEQUENCE; DNA PRIMERS; DOGS; FIBROSIS; HEART ATRIA; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TACHYCARDIA;

CANIS FAMILIARIS;

EID: 77952673305     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.12.020     Document Type: Article

References (43)

1. Tsai C.T., Lai L.P., Lin J.L., Chiang F.T., Hwang J.J., Ritchie M.D., Moore J.H., Hsu K.L., Tseng C.D., Liau C.S., Tseng Y.Z. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004, 109:1640-1646.
2. Goette A., Staack T., Röcken C., Arndt M., Geller J.C., Huth C., Ansorge S., Klein H.U., Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000, 35:1669-1677.
3. Li D., Shinagawa K., Pang L., Leung T.K., Cardin S., Wang Z., Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001, 104:2608-2614.
4. Willems R., Sipido K.R., Holemans P., Ector H., Van de Werf F., Heidbuchel H. Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of atrial fibrillation. J Cardiovasc Electrophysiol 2001, 12:1387-1392.
5. Nattel S., Shiroshita-Takeshita A., Cardin S., Pelletier P. Mechanisms of atrial remodelling and clinical relevance. Curr Opin Cardiol 2005, 20:21-25.
6. Vermes E., Tardif J.C., Bourassa M.G., Racine N., Levesque S., White M., Guerra P.G., Ducharme A. Enalapril decreased the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003, 107:2926-2931.
7. Komuro I., Kaida T., Shibazaki Y., Kurabayashi M., Katoh Y., Hoh E., Takaku F., Yazaki Y. Stretching cardiac myocytes stimulates proto-oncogene expression. J Biol Chem 1990, 265:3595-3598.
8. Nattel S. New ideas about atrial fibrillation 50years on. Nature 2002, 415:219-226.
9. Goette A., Lendeckel U., Klein H.U. Signal transduction systems and atrial fibrillation. Cardiovasc Res 2002, 54:247-258.
10. Li D., Fareh S., Leung T.K., Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999, 100:87-95.
11. Ferrario C.M. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 2006, 47:515-521.
12. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000, 87:E1-E9.
13. Santos R.A., Ferreira A.J., Nadu A.P., Braga A.N., de Almeida A.P., Campagnole-Santos M.J., Baltatu O., Iliescu R., Reudelhuber T.L., Bader M. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 2004, 17:292-299.
14. Iwata M., Cowling R.T., Gurantz D., Moore C., Zhang S., Yuan J.X., Greenberg B.H. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 2005, 289:H2356-H2363.
15. Grobe J.L., Mecca A.P., Lingis M., Shenoy V., Bolton T.A., Machado J.M., Speth R.C., Raizada M.K., Katovich M.J. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007, 292:H736-H742.
16. Tallant E.A., Ferrario C.M., Gallagher P.E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005, 289:H1560-H1566.
17. Grobe J.L., Mecca A.P., Mao H., Katovich M.J. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006, 290:H2417-H2423.
18. Morillo C.A., Klein G.J., Jones D.L., Guiraudon C.M. Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995, 91:1588-1595.
19. Wijffels M.C., Kirchhof C.J., Dorland R., Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995, 92:1954-1968.
20. Hanna N., Cardin S., Leung T.K., Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004, 63:236-244.
21. Kumagai K., Nakashima H., Urata H., Gondo N., Arakawa K., Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003, 41:2197-2204.
22. Boldt A., Wetzel U., Weigl J., Garbade J., Lauschke J., Hindricks G., Kottkamp H., Gummert J.F., Dhein S. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003, 42:1785-1792.
23. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 1997, 80:772-781.
24. Ausma J., Wijffels M., Thoné F., Wouters L., Allessie M., Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997, 96:3157-3163.
25. Wijffels M.C., Kirchhof C.J., Dorland R., Power J., Allessie M.A. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997, 96:3710-3720.
26. Everett T.H., Li H., Mangrum J.M., McRury I.D., Mitchell M.A., Redick J.A., Haines D.E. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 2000, 102:1454-1460.
27. Ausma J., van der Velden H.M., Lenders M.H., van Ankeren E.P., Jongsma H.J., Ramaekers F.C., Borgers M., Allessie M.A. Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation 2003, 107:2051-2058.
28. Nattel S., Li D. Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000, 87:440-447.
29. Nakashima H., Kumagai K. Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J 2007, 71:1977-1982.
30. Finkielstein D., Schweitzer P. Role of angiotensin-converting enzyme inhibitors in the prevention of atrial fibrillation. Am J Cardiol 2004, 93:734-736.
31. Allessie M.A., Boyden P.A., Camm A.J., Kléber A.G., Lab M.J., Legato M.J., Rosen M.R., Schwartz P.J., Spooner P.M., Van Wagoner D.R., Waldo A.L. Pathophysiology and prevention of atrial fibrillation. Circulation 2001, 103:769-777.
32. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000, 275:33238-33243.
33. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002, 277:14838-14843.
34. Zisman L.S., Keller R.S., Weaver B., Lin Q., Speth R., Bristow M.R., Canver C.C. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 2003, 108:1707-1712.
35. Averill D.B., Ishiyama Y., Chappell M.C., Ferrario C.M. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 2003, 108:2141-2146.
36. Huentelman M.J., Grobe J.L., Vazquez J., Stewart J.M., Mecca A.P., Katovich M.J., Ferrario C.M., Raizada M.K. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005, 90:783-790.
37. Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S., Lu S., Tikellis C., Grant S.L., Lew R.A., Smith A.I., Cooper M.E., Johnston C.I. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005, 26:369-375.
38. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.P., Speth R., Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003, 100:8258-8263.
39. Tallant E.A., Clark M.A. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003, 42:574-579.
40. Gallagher P.E., Ferrario C.M., Tallant E.A. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol 2008, 295:C1169-C1174.
41. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., van Gilst W.H. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002, 105:1548-1550.
42. Ishiyama Y., Gallagher P.E., Averill D.B., Tallant E.A., Brosnihan K.B., Ferrario C.M. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004, 43:970-976.
43. Liu E., Xu Z., Li J., Yang S., Yang W., Li G. Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling. Int J Cardiol 2009, Sep 2. [Electronic publication ahead of print]. doi:10.1016/j.ijcard.2009.07.015.